Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
Certara, Inc. (CERT)
Company Research
Source: GlobeNewswire
RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies. The Roadmap marks a pivotal moment in drug development. Companies that act now can future-proof their portfolios, gaining competitive advantage through faster timelines, lower costs, and stronger predictive evidence. Globally, there are thousands of monoclonal antibodies and antibody-drug conjugates (ADCs) currently in the preclinical phase of development1 across a broad range of therapeutic areas. Monoclonal antibodies are a key area in efforts to reduce animal testing, as biosimulation models often predict human outcomes as well as or better than, traditional animal studies. For over two decades, Certara has partnered with biopharmaceutica
Show less
Read more
Impact Snapshot
Event Time:
CERT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERT alerts
High impacting Certara, Inc. news events
Weekly update
A roundup of the hottest topics
CERT
News
- Certara (NASDAQ:CERT) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- Certara (NASDAQ:CERT) had its price target lowered by analysts at Stephens from $15.00 to $12.00. They now have an "overweight" rating on the stock.MarketBeat
- Certara (CERT) Valuation Check as New CEO Jon Resnick Takes Over and Outlook Is Reaffirmed [Yahoo! Finance]Yahoo! Finance
- Certara Appoints Jon Resnick as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Certara Appoints Jon Resnick as Chief Executive OfficerGlobeNewswire
CERT
Earnings
- 11/6/25 - Beat
CERT
Sec Filings
- 12/11/25 - Form 8-K
- 11/25/25 - Form SCHEDULE
- 11/12/25 - Form 4
- CERT's page on the SEC website